viewImmuPharma PLC

ImmuPharma firmly committed to Lupuzor ahead of managed access programme

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM),says lupus treatment Lupuzor will be entered into managed access programme to allow sufferers whose doctors recommend it.

Immupharma will get 'real-world' data from the MAP with up to 500 patients to receive the drug free of charge for two years.

That is more than twice the number of patients studied in all clinical trials for Lupuzor to date.

One big advantage is that' real-world' data can be used to supplement a regulatory filing.

Merck's Keytruda I/O cancer treatment made use MAP extensively for example.

An extension study to Lupozor's phase III study will also report next year, said McCarthy.

Quick facts: ImmuPharma PLC

Price: 7.5 GBX

Market: AIM
Market Cap: £12.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...



Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst

Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly...

on 11/9/19

2 min read